Prasanna Kumar
YOU?
Author Swipe
View article: Supplementary Figure S1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Figure S1. Swimmer plot of tumor response over time
View article: Supplementary Tables 1-4 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Tables 1-4 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Tables 1-4
View article: Supplementary Figure S2 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S2 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Figure S2. DXd immunohistochemistry in a patient treated with 6.4 mg/kg DS-6157a (A) pre-treatment and (B) on treatment (Cycle 2, Day 10)
View article: Depression, Anemia, and Physical Activity in Women with and without Diabetes: A Cross-sectional Study
Depression, Anemia, and Physical Activity in Women with and without Diabetes: A Cross-sectional Study Open
Introduction: Diabetes is a major public health concern that is increasing significantly in India. Women are mentally and physically affected by diabetes for various reasons. This study assessed depression, anemia, and physical activity in…
View article: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes: Findings from PIONEER REAL India
Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes: Findings from PIONEER REAL India Open
Introduction: The PIONEER REAL India study assessed the effectiveness of oral semaglutide in adults with type 2 diabetes (T2D). Methods: This was a 34–44-week, multicenter, non-interventional study in participants who had not previously re…
View article: Supplementary Data1 from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias
Supplementary Data1 from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias Open
Supplementary Data
View article: Data from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias
Data from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias Open
Purpose:Acute myeloid leukemia (AML) is characterized by frequent mutations in FMS-like tyrosine kinase 3 (FLT3), overexpression of murine double minute 2 (MDM2), and TP53 wild-type (WT). Monotherapies targeting FLT3 frequent…
View article: Routine Histological Examination of Prepuce in Pathological Phimosis: A Recommended Sustainable Practice
Routine Histological Examination of Prepuce in Pathological Phimosis: A Recommended Sustainable Practice Open
Background Phimosis is a frequent indication for pediatric outpatient referral. Pathological phimosis results from chronic inflammatory changes, often with lichenoid changes resulting in a hypopigmented indurated preputial plaque. Treatmen…
View article: Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i> -ITD Mutant/ <i>TP53</i> Wild-type Acute Myeloid Leukemias
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i> -ITD Mutant/ <i>TP53</i> Wild-type Acute Myeloid Leukemias Open
Purpose: Acute myeloid leukemia (AML) is characterized by frequent mutations in FMS-like tyrosine kinase 3 (FLT3), overexpression of murine double minute 2 (MDM2), and TP53 wild-type (WT). Monotherapies targeting FLT3 frequently result in …
View article: Characterization of Treatment Intensified (Add-on to Metformin) Adults with Type 2 Diabetes: Real-world Clinical Experience (Cardiovascular Outcomes and Value in the Real-world with Glucagon-like Peptide-1 Receptor Agonists) from India in 2008 to 2017
Characterization of Treatment Intensified (Add-on to Metformin) Adults with Type 2 Diabetes: Real-world Clinical Experience (Cardiovascular Outcomes and Value in the Real-world with Glucagon-like Peptide-1 Receptor Agonists) from India in 2008 to 2017 Open
Objective: The cardiovascular outcomes and value in the real world with GLP-1 receptor agonists study characterized demographics and medication usage patterns in treatment intensified (add-on to metformin) adults with type 2 diabetes (T2D)…
View article: When the Breather Bleeds and the Bleeder Strives – A Rare Manifestation of an Unrare Disease
When the Breather Bleeds and the Bleeder Strives – A Rare Manifestation of an Unrare Disease Open
A BSTRACT Diffuse alveolar hemorrhage is a life-threatening condition that could be due to various factors, such as infections, vasculitis, malignancy, etc., Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by …
View article: Supplementary Figure S2 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S2 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor Open
Supplementary Figure S2. DXd immunohistochemistry in a patient treated with 6.4 mg/kg DS-6157a (A) pre-treatment and (B) on treatment (Cycle 2, Day 10)
View article: Supplementary Figure S1 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S1 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor Open
Supplementary Figure S1. Swimmer plot of tumor response over time
View article: Data from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor
Data from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor Open
Purpose: To evaluate DS-6157a, an antibody-drug conjugate targeting G-protein coupled receptor 20 (GPR20), in gastrointestinal stromal tumors (GIST). Patients and methods: In this phase 1 multicenter, open-label, multiple-dose study, patie…
View article: Supplementary Tables 1-4 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor
Supplementary Tables 1-4 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor Open
Supplementary Tables 1-4
View article: Supplementary Appendix 1 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor
Supplementary Appendix 1 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor Open
Supplementary Appendix
View article: Supplementary Figure S1 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S1 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor Open
Supplementary Figure S1. Swimmer plot of tumor response over time
View article: Supplementary Figure S2 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S2 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor Open
Supplementary Figure S2. DXd immunohistochemistry in a patient treated with 6.4 mg/kg DS-6157a (A) pre-treatment and (B) on treatment (Cycle 2, Day 10)
View article: Supplementary Appendix 1 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor
Supplementary Appendix 1 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor Open
Supplementary Appendix
View article: Supplementary Tables 1-4 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor
Supplementary Tables 1-4 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor Open
Supplementary Tables 1-4
View article: Phase 1 dose escalation study of the <scp>MDM2</scp> inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies
Phase 1 dose escalation study of the <span>MDM2</span> inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies Open
Background Mouse double minute‐2 homolog (MDM2) plays a key role in downregulating p53 activity in hematologic malignancies, and its overexpression is associated with poor outcomes. Methods This phase 1 study assessed the safety and effica…
View article: Data from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Data from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Purpose:To evaluate DS-6157a, an antibody–drug conjugate targeting G protein–coupled receptor 20 (GPR20), in gastrointestinal stromal tumors (GIST).Patients and Methods:In this phase I multicenter, open-label, multiple-dose study, patients…
View article: Supplementary Figure S1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Figure S1. Swimmer plot of tumor response over time
View article: Supplementary Tables 1-4 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Tables 1-4 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Tables 1-4
View article: Supplementary Appendix 1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Appendix 1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Appendix
View article: Supplementary Figure S2 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S2 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Figure S2. DXd immunohistochemistry in a patient treated with 6.4 mg/kg DS-6157a (A) pre-treatment and (B) on treatment (Cycle 2, Day 10)
View article: Supplementary Figure S1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Figure S1. Swimmer plot of tumor response over time
View article: Supplementary Appendix 1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Appendix 1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Appendix
View article: Supplementary Figure S2 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S2 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Figure S2. DXd immunohistochemistry in a patient treated with 6.4 mg/kg DS-6157a (A) pre-treatment and (B) on treatment (Cycle 2, Day 10)
View article: Supplementary Tables 1-4 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Tables 1-4 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor Open
Supplementary Tables 1-4